To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

Zeria Pharmaceutical

Status and phase: Completed; Phase 2

Conditions: Functional Dyspepsia

Treatments: Drug: Z-338

Study type: Interventional

Funder types: Industry

Identifiers

NCT00323817

99010206E

Details and patient eligibility

About

To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

Enrollment: 282 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects presenting diagnosis of FD as defined by the Rome II
• Subjects presenting postprandial fullness and/or Early satiety should be the most bothersome symptom

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind